Flutiform, a new steroid/long-acting beta-agonist inhaler
نویسندگان
چکیده
منابع مشابه
Indacaterol: a new once daily long-acting beta2 adrenoceptor agonist
INTRODUCTION Indacaterol is a novel once daily long-acting beta agonist (LABA) developed for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. AIMS This review summarizes preclinical and clinical data of indacaterol, including all data generated during the phase II trial program, and further discusses the outlook and potential of the drug in the future treatment of COP...
متن کاملChanges to inhaled corticosteroid dose when initiating combination inhaler therapy in long-acting beta agonist naïve patients with asthma: a retrospective database analysis
Retrospective prescribing data were obtained from 46 general practice surgeries in NHS Scotland. Patients with asthma who were naïve to previous LABA therapy and initiated combination inhaler therapy in 2008-2009 were classified according to the ICS dose in their combination inhaler compared to the highest dose of ICS they received before initiation. Among the 685 patients (541 [79.0%] who had ...
متن کاملSalmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.
Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal experiments to produce a more prolonged bronchodilator effect than currently available beta 2 adrenoceptor agonists. It was studied in eight adult asthmatic patients. Each patient received on separate test days salbutamol 200 micrograms and salmeterol 50, 100, and 200 micrograms according to a randomised, do...
متن کاملFormoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma.
Sixteen patients with stable chronic asthma participated in a double blind crossover study comparing the new inhaled long acting beta 2 agonist formoterol with salbutamol. Inhaled (n = 15) and oral steroid (n = 1) treatment were maintained at the same daily dose throughout the study. For four weeks the patients received either formoterol 24 micrograms twice daily or salbutamol 400 micrograms tw...
متن کاملOveruse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability.
BACKGROUND Overuse of short-acting beta-agonists (SABA) is described in asthma, but little is known about overuse of SABA in chronic obstructive pulmonary disease (COPD). METHODS Prospective 3-month cohort study of patients with moderate-to-severe COPD who were provided a portable electronic inhaler sensor to monitor daily SABA use. Subjects wore a pedometer for 3 seven-day periods and were a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prescriber
سال: 2013
ISSN: 0959-6682
DOI: 10.1002/psb.1043